chr19-4090589-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BP4_StrongBP6_ModerateBS2
The NM_030662.4(MAP2K2):c.*9G>A variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000601 in 1,548,126 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).
Frequency
Genomes: 𝑓 0.000085 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000057 ( 0 hom. )
Consequence
MAP2K2
NM_030662.4 3_prime_UTR
NM_030662.4 3_prime_UTR
Scores
2
Clinical Significance
Conservation
PhyloP100: -1.91
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -10 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 19-4090589-C-T is Benign according to our data. Variant chr19-4090589-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 46224.Status of the report is criteria_provided_single_submitter, 1 stars.
BS2
High AC in GnomAd4 at 13 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAP2K2 | NM_030662.4 | c.*9G>A | 3_prime_UTR_variant | 11/11 | ENST00000262948.10 | NP_109587.1 | ||
MAP2K2 | XM_006722799.3 | c.*9G>A | 3_prime_UTR_variant | 9/9 | XP_006722862.1 | |||
MAP2K2 | XM_047439100.1 | c.*9G>A | 3_prime_UTR_variant | 9/9 | XP_047295056.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MAP2K2 | ENST00000262948.10 | c.*9G>A | 3_prime_UTR_variant | 11/11 | 1 | NM_030662.4 | ENSP00000262948 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152218Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
13
AN:
152218
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000580 AC: 9AN: 155254Hom.: 0 AF XY: 0.0000609 AC XY: 5AN XY: 82106
GnomAD3 exomes
AF:
AC:
9
AN:
155254
Hom.:
AF XY:
AC XY:
5
AN XY:
82106
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000573 AC: 80AN: 1395908Hom.: 0 Cov.: 31 AF XY: 0.0000581 AC XY: 40AN XY: 688704
GnomAD4 exome
AF:
AC:
80
AN:
1395908
Hom.:
Cov.:
31
AF XY:
AC XY:
40
AN XY:
688704
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000854 AC: 13AN: 152218Hom.: 0 Cov.: 33 AF XY: 0.0000941 AC XY: 7AN XY: 74358
GnomAD4 genome
AF:
AC:
13
AN:
152218
Hom.:
Cov.:
33
AF XY:
AC XY:
7
AN XY:
74358
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Likely benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 13, 2012 | *9G>A in the '3UTR of MAP2K2: This variant is not expected to have clinical sign ificance because variants affecting mRNA translation have not been associated wi th MAP2K2 and Noonan syndrome. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at